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of recession and economic adjustment policies set by the IMF and 
the World Bank. 
The proponents for BI claim a few successful experiences in 
which the initiative is based: the PAHOU project (Benin) is one of 
the most often quoted among others. But in fact there are many 
experiences for PHC community financing that started in the second 
half of the 170s. Cameroon, Ghana, Mali, Niger, Nigeria, Senegal, 
Tanzania, Sudan and Zaire are countries, where NGOs, religious 
organizations or governmental programs of different styles and 
sizes, have been in progress (some of these were initiated in 1955 
or even earlier like the Aga Khan Health Services in Tanzania, 
which started in 1941). 
The supporters of the BI are quick to assert that the 
principles of "equity" are not at risk. There are other notions 
attached to the initiative: revitalization of PHC; decentralization 
to the district level and community participation. Other recurrent 
concepts in the BI discourse are the purchase and distribution of 
"essential drugs", and the promotion of a "rational use of drugs". 
Most, if not all, of these notions are centred around iK Western 
conceptions about health care and the utilization of modern 
pharmaceuticals. 
4 
In short, it seems to me that the BI represents a set of 
debatable principles and undefined notions, which underestimated 
a wealth of participatory experiences in Africa and other 
developing regions, sometimes manipulated and often misinterpreted 
many of the research findings. I contend that the BI -as it stands- 
is largely based in Western medical traditions, which are at least 
controversial and may negatively affect the goals of equity, 
comprehensive PHC and genuine social participation in health and 
development. From this perspective, the following are the major 
limitations and debatable points I propose to discuss briefly in 
this presentation: 
- the BI cannot be seen in isolation. The BI should be seen 
as part of a larger frame of initiatives: the GOBI-FFF 
selective PHC approach for MCH, and the structural adjustment 
policies emanating from the World Bank and the IMF. 
- the selective PHC which BI belongs to, represents in the 
long run the depolitization (decontextualization) of health 
and the naturalization of poverty. 
- the BI tends to reinforce the equivocal image that health 
could be improved through the increased availability of 
medical resources. Availability of drugs and pharmaceuticals 
are seen as a visible and tangible proof of increasing well 
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being. This image is deeply rooted in the biomedical model of 
health, which some authors have identified as "commodified 
health". In exporting the Western model of health care, 
commodified health plays an important role as a fetish of 
modernization (Nichter, 1989), reinforcing the reductionistic 
causation model of disease (one agent, one disease) and the 
decontextualisation (depolitization) of health. 
The commodification of health and the naturalization of poverty. 
In discussing the consequences of health commodification for 
community health, Mark Nichter asserts that: 
"A false sense of security has emerged from the 
exaggerated claims of curative and preventive health 
fixes. At the time of environmental deterioration, rapid 
urbanization and industrialization, a mystification of 
health has occurred resulting in a depreciation of social 
responsibility ... Health has been decontextualized and 
medicalized. It has been turned into an individual 
pursuit in which commodified health is purchased in the 
form of medicines and doctor-patient encounters are 
reduced to an exchange of drugs as the measure of a 
meaningful transaction. Embodied in such a transaction 
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is an ideology consistent with a set of values associated. 
with consumerism and the growth of the capitalist state. 
In community health terms, the (social) cost of such 
growth is high." (text in parenthesis mine. Nichter, 
1989: p 262-263). 
Heavy reliance on medications to treat common symptoms and 
morbidity episodes such as colds, cough and diarrhoea, parasite 
infestations, etc. results in "...a cycle of disease-treatment- 
disease" that will largely benefit the pharmaceutical companies but 
does not alter the situation under which people live, neither the 
nutritional and environmental conditions which account for much of 
their illnesses (Ferguson, 1988). Further, if the people has to 
bear the cost of this cycle, resources are drained away without 
providing in return any improvement in the living conditions of the 
population. 
This is not the place nor the time to discuss at length the 
inadequacies of the selective PHC approach to health, but let me 
briefly summarize the main reservations I hold, with respect to 
this approach for the African (and other regions) countries: 
- the GOBI-FFF set of interventions are essentially medical 
solutions to social problems. It claims that selective medical 
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interventions can improve health indices without necessarily 
improving the social and natural environment. 
- the overall strategy of selective PHC focuses on products 
not processes. The products (i.e. ORS, contraceptives, drugs, 
vaccines, etc) are introduced into communities via mass media 
campaigns, and social marketing approaches -as in the case 
of the BI- where direct payment for drugs is justified as a 
mechanism for cost recovery and financing of health care. The 
approach of introducing medical technologies (such as drugs 
and pharmaceuticals) through social marketing techniques is 
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a risky enterprise and should not be considered harmless. The 
patterns of prescription (both professional and "over the 
counter") and self-medication are already affected by a 
growing number of pharmaceutical products in the "official 
list" of Ministries of Health, the growing smuggling of modern 
drugs (faked or real) and the marketing techniques being used 
for introducing medicinal drugs through conventional outlets 
and other commercial channels. It has been widely recognized, 
that the range and number of medicinal products made available 
is significantly influenced, if not largely determined, by the 
profit needs of the industry, not the health needs of the 
country as defined by epidemiological or nutritional data. 
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- the social marketing plus selective medical interventions 
approach, with intensive use of technologies usually produced 
at the centre far from the village, undermines the utilization 
of indigenous skills and local medical knowledge, further 
implying that diseases are not socially determined, but result 
from ignorance and poor hygienic habits of individuals (the 
blame of the victim). 
- it has been widely recognized -both in traditional and 
modern societies- that medicinal drugs are not the only form 
of therapy. There are many others, from surgery to exorcism, 
from meditation to fasting and praying. But perhaps the most 
important difference lies in that most therapies are generated 
and delivered within the family setting or the community, or 
administered by an specialist (i.e. surgery or exorcism), 
while the medicinal drugs could be prescribed and used (and 
this is often the case in developing countries) independently 
from a practitioner, usually as a form of self-care. This has 
been described as the "paradox of self-care", that is the use 
of self-prescribed medicines implies greater self-reliance in 
one sense, but less in another (Whyte and Van der Geest, 1988) , 
which is another form of dependency: a distant dependency with 
the manufacturer and the pharmaceutical industry. 
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- the S-PHC/social marketing approach incorporates health 
technologies manipulating community organizations in order to 
transform them into instruments for the delivery of a 
"package" (Kanji, 1989). The participation of people and local 
organizations are seen as conduits, or delivery points. This 
kind of community participation is instrumental and not 
transformative. People are seen as "acceptors" and/or "users", 
"respondents" of KAP surveys at best and "recipients" of 
messages, but not as transformers of their own situation, co- 
makers of decisions regarding the introduction and utilization 
of health technologies. 
Although is difficult to find reliable statistics, marketing 
surveys suggest that developing nations account for about 200 of 
the world pharmaceutical consumption and that there is considerable 
variation among the various regions: medicines consumption is 
significantly higher in Latin America and Asia, than in Africa. 
The provision of manufactured drugs and pharmaceuticals in 
large scale should undoubtedly have effects on local medical 
traditions and the existing health-seeking processes at the 
family and the community level: the decision making at the 
household level, the patterns of therapy seeking, the popular 
and folk explanatory models, etc... There are many studies 
focusing on the consequences for human health of promotional 
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and sales practices, the impact of pharmaceuticals on public 
health budgets in Third World countries, but relatively little 
attention has been paid to the effects of pharmaceutical 
industries on alternative medical traditions or means of 
coping with illness (Ferguson, 1988). 
In short, the selective approach of the BI represents the 
commodification of health and the naturalization of poverty. The 
approach often results in the infatuation of Ministries of Health 
with the 'quick fix' social marketing and selective PHC seem to 
offer (Wisner, 1988). This set of principles are usually based in 
very tenuous or even contradictory research evidence. 
Cost recovery and community financing mechanisms. 
Let me turn now the analysis to the economic perspectives of 
the BI: the issues of cost recovery systems and drug revolving 
funds. 
Any cost recovery system would discriminate against a 
considerable proportion of the poor sectors of the population, 
perhaps those in greatest need for services. Many studies have 
reported a clear reduction in the use of health services, after 
the introduction of any form of payment. For instance, Yoder (1989) 
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reported significant decline in overall patient use of health 
services in Swaziland, following a nationwide increase in user 
fees. Following the fees increase, average attendance decreased at 
government facilities by 32.4% and increased in Mission facilities 
by 10.2%, leading to an overall decrease of about 17%. When looking 
at patient visits for basic and preventive services such as 
inmmunizations (BCG and DPT) or oral rehidration visits, the 
average attendance declines were -18% and -24% respectively. 
The strategies for cost recovery inevitably reduces the role 
of the state, transferring the costs and responsibilities from 
governments to people. It encourages the privatization of health 
and separates health from economic and social development... 
On the other hand, people's willingness to pay does not reflect 
their ability to pay for services (if some incur in large debts for 
paying private medical care and drugs it represents the no choice 
situation). Thus, while the "willing and able to pay" rationale may 
be shown has one of the main arguments for introducing fees for 
drugs and/or services, it raises many questions, so far unanswered 
in the BI. For instance, what happens when "willing and alble to 
pay data" are dissagregated by different groups of users, by 
different ethnic and socioeconomic groups or by type of services 
(I.E. preventive vs curative)? When fees are raised, how are the 
costs and benefits distributed across the population? (Yoder, 
1989). What is the the impact of cost recovery in prescription 
- 12 - 
patterns and how does it affects the quality of services? What is 
the impact of higher fees on services utilization and on the 
morbidity and mortality levels of the population, among the 
different social classes and ethnic groups? 
The implementation of an efficient and equitable cost recovery 
system (i.e. revolving drug fund) for PHC requires fairly 
sophisticated planning and managerial capabilities to overcome the 
logistical problems derived from operating under extremely unstable 
conditions (i.e. high inflation rates, poor communications, fuel 
shortages, political instability, etc) prevailing in developing 
countries. (i.e.since revenues are likely to be in local currency, 
how is this going to help the purchase of drugs overseas in a high 
inflation economy). Reliable and periodic information on 
quantities and revenues by drug will be required to determine the 
current prices to be charged. This could be complicated further 
when there are subsidies and surcharges for certain drugs or 
treatments to be detracted, and exemptions for certain groups. The 
administration of all these may turn to be chaotic; and 
misappropriation and/or mismanagement of funds could easily occur 
BI fails to specify who will decide how the money from drugs 
are to be used. It is the community representatives or the health 
services personnel who decides who pays, how much, and what will 
be the destiny of the revenues ? Discretionary powers are going to 
- 13 - 
rest with the health staff who will come under strong pressure to 
exempt payment for friends, relatives or others whom they feel 
obliged. To be classified under "indigent" or any other category 
represents another stigma for people to feel humiliated or 
discriminated against. 
Under the influence of a large number of medicinal drugs, what 
will be the resulting configuration of the local health services 
and programmes ? If the whole system is going to be centred on 
drugs and modern pharmaceuticals, most likely the emphasis will be 
on curative rather than preventive programs. 
Finally, if salaries of the health personnel are going to be 
dependent on drug/treatment cost-recovery profits, then 
prescription patterns are going to be heavily distorted, favouring 
the use of certain drugs and procedures. If promotion and 
prevention are going to be administered free of charge, then we can 
actually be distorting the composition of services delivered, with 
negative consequences for the PHC system as a whole. 
In closing, let me make a final comment in reference to the 
notion of cost recovery and community financing: 
We should recognize that cost recovery and "drug revolving 
fund" have different connotations, and should not be considered the 
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only community financing method. In fact, there ,re three main 
strategies for community financing: direct payment for drugs, fee- 
": 
for-serv*60 and health insurance. 
It according to some oflioial eat*wates (World Rank) too 1990 
1995 GNP of low 1nco s pAn cPyntries a Aging r , 0e eve,0 lowex 
than in 1973-1980, (the qfowth rate of G ",P fox how luoome syb 
Sa4ran Xfrip& 1955 to 19a3 was 4.251k) the dile(nnla is 40ubI4, t 
First, how people Ore going to-pay for it._? and secgnd, how ̀is tAe 
government going to pay for it ? (a large public sector with 
average shares of public health expenditures in 9NP of 0.95 and 
1.9* for low and *iddle income sub-Saharan Africa 
In facing this dilemma the obvious alternatives for community 
financing are as follows: 
-extra taxes for health (income and consumption); 
-lotteries (not very dependable, and even regressive since 
largest participation comes from low income groups); 
-re-allocation of government budget (i.e. from defehoe at 
general administration, a proposal very hard to implement); 
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-direct payment: user charges for health services or pre- 
payment; 
-community financing with some degree of involvement in the 
organization of the financing scheme, in the allocation of 
resources, in the administration of the revolving fund, etc. 
Within this set of alternatives the last strategy seems to me 
the most acceptable one, provided that drugs are not the ONLY 
reason for charging the community. In fact, education, nutrition, 
water or preventive services should be as important as drugs and 
pharmaceuticals. 
As a final point, I would like to suggest that in any 
financing strategy, the community should be involved in 
establishing and monitoring the rules of the game. In particular, 
the perceptions and the point of view of the people about the 
trustworthiness of the management of the system, the judgement on 
the ability to pay, the complete local recycling of funds, and 
their interpretation of equity, all need to be considered in 
selecting and implementing a set of community financing strategies 
(Carrin, 1987). Minimum knowledge in accounting and management of 
revenues is essential in the direct payment financing scheme (fee- 
for-service requires additional capacity to cost inputs and set of 
I Imn inn iim uiu nni mii nn uii 
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appropriate fees; pre-payment strategies needs actuarial 
knowledge). 
Above all, more research is needed re ardiag the. effocts of 
modern pharmaceuticals in health care systems, and the impact of 
the introduction of medicinal drugs on mortality and morbidity 
profiles in developing market economies. OA the same vein, More in- 
depth information about the population's socioeconomic status and 
its preferences, including their health seeking behavioral model 
and their actual managsrial capabilities are badly needed, BEFORE 
policy decisions and top-down "initiatives" are formulated on how 
to finance a health care system in a given country acommunity. 
